Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy
Bookmark1. The objective response rate was 29.8% (1% complete response, 66% partial response) with...
Read MoreSep 19, 2023
Bookmark1. The objective response rate was 29.8% (1% complete response, 66% partial response) with...
Read MoreSep 13, 2023
Bookmark1. Pooled overall survival and progression-free survival HR were found to be 0.95 and 0.88...
Read MoreSep 2, 2023
Bookmark1. This post-hoc analysis of the AMATERASU randomized clinical trial found that, for...
Read MoreAug 31, 2023
Bookmark1. In a cross-sectional study, adolescent survivors of childhood cancers were more...
Read MoreAug 31, 2023
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read MoreAug 25, 2023
Bookmark1. The risk of mortality from solid cancer, lagged by 10 years, is estimated to be...
Read MoreAug 22, 2023
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read MoreAug 22, 2023
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read MoreAug 19, 2023
Bookmark1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer...
Read MoreAug 16, 2023
Bookmark1. Median overall survival in the atezolizumab group was 10.3 months versus 9.2 months in...
Read MoreAug 15, 2023
Bookmark1. The pathological complete response rate for the experimental group was improved...
Read MoreAug 15, 2023
Bookmark1. At 24 months, more participants in the pembrolizumab group were alive without an event,...
Read MoreAug 10, 2023
Bookmark1. In this systematic review, seven core elements of a good death among cancer patients...
Read MoreAug 9, 2023
Bookmark1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide...
Read MoreAug 8, 2023
Bookmark1. Initiating colorectal cancer screening at age 45 results in 12,188 fewer cases and...
Read MoreAug 8, 2023
Bookmark1. The immune subtype demonstrated an improved progression-free survival (HR 0.37) and...
Read MoreAug 5, 2023
Bookmark1. In this systematic review, most articles reported a positive association between...
Read MoreAug 2, 2023
Bookmark1. Progression-free and overall survival was comparable in both the intervention and...
Read MoreJul 29, 2023
Bookmark1. In this prospective cohort study, higher cardiorespiratory fitness (CRF) was associated...
Read MoreJul 20, 2023
Bookmark1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2....
Read More